Mirador Therapeutics licenses anti-C5a antibody from Kira Pharmaceuticals
Mirador Therapeutics has entered into an exclusive worldwide license agreement with Kira Pharmaceuticals for KP-301, a potentially long-acting, sweeping anti-C5a antibody designed to inhibit C5a/C5aR-mediated inflammation. The agreement expands Mirador’s precision immunology portfolio into inflammatory vascular disease. Kira will receive $12 million upon signing. The… Read More